Truist initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $11 price target Ibtrozi’s FDA approvoal positions Nuvation Bio as a commercial-stage player in precision oncology, notes the analyst, who likes the launch set-up “led by a proven team” and supported by Ibtrozi’s competitive profile in ROS1 non-small cell lung cancer.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: